PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50120C00177 — TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS.

TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. is a federal NONE award for Department of Health and Human Services (HHS) held by VEDANTA BIOSCIENCES, INC.. Estimated value $99.1M ($91.8M obligated). Current period of performance ends Aug 31, 2027 (potential Dec 31, 2031). Last award drew 1 bidder. Place of performance: BOSTON, MA. Related solicitation BAA-18-100-SOL-00003.

$99.1M
Estimated Value
$91.8M
Obligated
Aug 31, 2027
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

VEDANTA BIOSCIENCES, INC. holds $43.0M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Aug 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75A50120C00177
AgencyDepartment of Health and Human Services (HHS)
IncumbentVEDANTA BIOSCIENCES, INC.
UEIC91JJXT9QND5
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAZ13
Place of performanceBOSTON, MA
Related solicitationBAA-18-100-SOL-00003
PoP end (current)Aug 31, 2027
PoP end (w/ options)Dec 31, 2031
Obligated$91.8M

TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS.

Recompete timing

Public
Expiring in 380 days

Current PoP ends Aug 31, 2027 (380 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Watch this contract — one email →

Incumbent footprint

Public record

VEDANTA BIOSCIENCES, INC.$43.0M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$43.0M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open VEDANTA BIOSCIENCES, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50120C00177?

75A50120C00177 (TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS.) is a Department of Health and Human Services (HHS) award with an estimated value of $99.1M, currently held by VEDANTA BIOSCIENCES, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50120C00177?

VEDANTA BIOSCIENCES, INC. is the incumbent with $43.0M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2027.

When does 75A50120C00177 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50120C00177